



## Ironwood Pharmaceuticals to Present at the Bank of America Merrill Lynch Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- [Ironwood Pharmaceuticals, Inc.](http://www.ironwoodpharma.com) (NASDAQ: IRWD) will present a corporate update at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 17, 2017 at 1:00 p.m. Pacific Time / 4:00 p.m. Eastern Time in Las Vegas, Nevada.

A live webcast of Ironwood's presentation will be accessible through the Investors section of the company's website at [www.ironwoodpharma.com](http://www.ironwoodpharma.com). To access the webcast, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Ironwood's website for 14 days following the conference.

### About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is a commercial biotechnology company focused on creating medicines that make a difference for patients, building value for our fellow shareholders, and empowering our passionate team. We are commercializing two innovative primary care products: linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), and lesinurad, which is approved to be taken with a xanthine oxidase inhibitor (XOI) for the treatment of hyperuricemia associated with uncontrolled gout. We are also advancing a pipeline of internally and externally generated innovative product candidates in areas of significant unmet need, including uncontrolled gastroesophageal reflux disease and vascular and fibrotic diseases. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. For more information, please visit [www.ironwoodpharma.com](http://www.ironwoodpharma.com) or [www.twitter.com/ironwoodpharma](https://www.twitter.com/ironwoodpharma); information that may be important to investors will be routinely posted in both these locations.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20170510006181/en/>

Ironwood Pharmaceuticals, Inc.

*Media Relations*

Trista Morrison, 617-374-5095

Director, Corporate Communications

[tmorrison@ironwoodpharma.com](mailto:tmorrison@ironwoodpharma.com)

or

*Investor Relations*

Meredith Kaya, 617-374-5082

Senior Director, Investor Relations

[mkaya@ironwoodpharma.com](mailto:mkaya@ironwoodpharma.com)

Source: Ironwood Pharmaceuticals, Inc.

News Provided by Acquire Media